Dermatology and Therapy最新文献

{"title":"CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study.","authors":"David M Pariser, Mark G Lebwohl, Janusz Jaworski, Jakub Trefler, Stefan Daniluk, Anna Dudek, Wojciech Baran, Witold Owczarek, Pawel Brzewski, Mariusz Sikora, Marek Krogulec, SungHyun Kim, JeeHye Suh, EunJin Choi, JungBin Cha, HyunJin Lee, SungJeong Lee, John Y Koo","doi":"10.1007/s13555-025-01383-5","DOIUrl":"https://doi.org/10.1007/s13555-025-01383-5","url":null,"abstract":"<p><strong>Introduction: </strong>A 27-week analysis of this phase 3 study demonstrated the interchangeability of the adalimumab biosimilar CT-P17 and reference adalimumab. The current 52-week analysis reports secondary data from the open-label extension period (OLE) of the study.</p><p><strong>Methods: </strong>In this randomized, double-blind, active-controlled phase 3 study, adults with moderate-to-severe chronic plaque psoriasis received (via prefilled syringe) 80 mg subcutaneous reference adalimumab on day 1, then 40 mg 1 week later, and every other week (EOW) until week 11. At week 13, patients were randomized (1:1) to continue reference adalimumab (\"continuous\" group) or undergo repeated switching between CT-P17 and reference adalimumab (\"switching\" group) until week 25. Thereafter, patients entered an OLE and received 40 mg CT-P17 EOW from week 27 to 49, with an end-of-study visit at week 52. Here we present findings from the OLE. Pharmacokinetics (PK), efficacy (including mean percent improvement from baseline in Psoriasis Area Severity Index [PASI] score), safety, and immunogenicity were evaluated. Post hoc subgroup analyses were also conducted.</p><p><strong>Results: </strong>Of 327 patients who initiated the OLE, 152 and 160 patients from the switching group and continuous group, respectively, completed the study. Mean serum concentrations were similar between groups throughout the OLE. Efficacy improvements observed up to week 27 were maintained during the OLE and were comparable between groups. At week 52, overall mean (standard deviation [SD]) improvement from baseline in PASI score was 90.34% (16.59). Safety profiles were similar between groups, and immunogenicity did not increase during the OLE. The mean (SD) percent improvement from baseline in PASI score was slightly lower in patients who were antidrug antibody (ADA)-positive versus those who were ADA-negative (89.57 [17.27] versus 97.29 [4.08]) at week 52.</p><p><strong>Conclusions: </strong>PK, efficacy, safety, and immunogenicity findings remained consistent throughout the OLE, regardless of prior treatment, and were generally comparable across timepoints.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov: NCT05495568.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Disease Characteristics and Treatment Patterns in Mild-Moderate Psoriasis: Results from Real-World Clinical Practice in the United States (PROSPECT Study).","authors":"Emily J Goddard, James M Haughton, James E Lucas, Sophie G Barlow, Timothy P Fitzgerald, Alexander M Litvintchouk, David Wu","doi":"10.1007/s13555-025-01353-x","DOIUrl":"10.1007/s13555-025-01353-x","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriasis (PsO) is a common dermatological condition. Psoriasis severity is commonly characterized by percentage body surface area (BSA) affected, with < 3% BSA considered mild disease and 3-10% moderate disease. Treatment options for and knowledge of clinical practice patterns in patients with mild PsO are limited. Here, we use real-world data to characterize patients diagnosed with mild and moderate PsO and their clinical management.</p><p><strong>Methods: </strong>Data were derived from the Adelphi Real World PsO Disease Specific Programme™, a cross-sectional survey of dermatologists and adult patients with PsO in the USA, between December 2021 and March 2022. Dermatologists reported demographic and clinical details. Patients reported treatment satisfaction and quality of life using patient-reported outcome measures. Patients were stratified by physician-reported severity at diagnosis (mild/moderate) and compared using bivariate analyses.</p><p><strong>Results: </strong>Out of 389 patients, 18.5% were diagnosed with mild PsO. The majority were female, white, and employed. Patients diagnosed with moderate PsO had higher body mass index (p = 0.002) and longer disease duration (p = 0.041). Only 22.0% of patients diagnosed with mild PsO had BSA < 3% at diagnosis, and 48.1% of patients diagnosed as moderate PsO had BSA < 10%. BSA improvement following initiation of current treatment was higher among patients diagnosed with moderate PsO (p < 0.001). Those diagnosed with moderate PsO more commonly had involvement of the elbows (p = 0.003), legs (p = 0.002), knees (p < 0.001), soles (p = 0.035), and back (p = 0.004) at diagnosis. Cracked skin, redness, and tender skin (p < 0.001 for all) were more common among those diagnosed with moderate PsO. Both groups mostly received topical agents; however, those diagnosed with moderate PsO more commonly received systemic (p < 0.001) or biologic (p = 0.002) treatment. Patients diagnosed with moderate PsO had lower EQ-5D-5L (p = 0.014) and treatment satisfaction (p = 0.007) scores.</p><p><strong>Conclusion: </strong>These findings suggest that physicians routinely underestimate PsO severity, resulting in possible undertreatment, suboptimal outcomes, and quality-of-life impairments for patients with milder severity PsO.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"663-680"},"PeriodicalIF":3.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909323/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Accuracy of Polarized and Ultraviolet Fluorescence-Induced Dermoscopy in Scarring and Nonscarring Alopecias: a Retrospective Observational Multicentric Study.","authors":"Noemi Plozner, Nkechi Anne Enechukwu, Yasmeen J Bhat, Biswanath Behera, Paweł Pietkiewicz, Enzo Errichetti","doi":"10.1007/s13555-025-01355-9","DOIUrl":"10.1007/s13555-025-01355-9","url":null,"abstract":"<p><strong>Introduction: </strong>There is growing evidence that ultraviolet-induced fluorescence (UVF) dermoscopy may improve diagnostic accuracy in non-neoplastic dermatoses, yet data on hair disorders are scarce. The aim of this observational retrospective study was to compare the accuracy of polarized dermoscopy and UVF-dermoscopy in characterizing and distinguishing scarring and nonscarring alopecias.</p><p><strong>Methods: </strong>A total of 84 patients were enrolled, with 43 and 41 patients suffering from nonscarring and scarring alopecias, respectively. Analyzed variables included scarring findings (i.e., dotted/globular, structureless or perifollicular bright white areas on both polarized and UVF-dermoscopy) and follicular unit (i.e., hair or follicular ostia, with the latter appearing as empty follicular openings and follicular red/blue fluoresce on polarized and UVF-dermoscopy, respectively). Comparative analysis between polarized and UVF-dermoscopy in detecting the abovementioned features and differentiating scarring from nonscarring alopecias were performed, also assessing possible differences according to the skin tone. Interobserver agreement was evaluated for both dermoscopic settings.</p><p><strong>Results: </strong>UVF-dermoscopy was superior (p < 0.01) to polarized dermoscopy in detecting follicular ostia and white bright areas in general and fair-skinned patients, while only follicular ostia were better seen under this setting in skin of color. Additionally, UVF-dermoscopy was found to be more accurate (p < 0.01) in differentiating nonscarring from scarring alopecias when considering all and light phototypes. Finally, Kappa values were 0.57 and 0.83 for polarized and UVF-dermoscopy, respectively.</p><p><strong>Conclusions: </strong>UVF-dermoscopy may be a valuable and reliable complementary tool in differentiating scarring and nonscarring alopecias, especially in light phototypes.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"697-705"},"PeriodicalIF":3.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909344/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143472277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recommendations to Improve Outcomes in Acne and Acne Sequelae: A Focus on Trifarotene and Other Retinoids.","authors":"Naiem Issa, Andrew Alexis, Hilary Baldwin, Iltefat Hamzavi, Adelaide Hebert, Pearl Kwong, Edward Lain, Angela Moore, Omar Noor, Todd Schlesinger, Jonathan Weiss, Heather Woolery-Lloyd, J P York, Kate Zibilich Holcomb, Leon Kircik, Rajeev Chavda","doi":"10.1007/s13555-025-01344-y","DOIUrl":"10.1007/s13555-025-01344-y","url":null,"abstract":"<p><p>Acne vulgaris affects nearly 50 million people in the USA, ranking as the eighth most prevalent disease globally. This chronic inflammatory skin condition often results in sequelae, including atrophic acne scars, acne-induced macular erythema and acne-induced hyperpigmentation, impacting patients' quality of life. This commentary article reviews the use of topical retinoids, with a particular emphasis on trifarotene cream 0.005%, for managing both acne and acne sequelae. Topical retinoids are considered central to improving treatment outcomes because of their established efficacy, safety and tolerability. Adapalene, tretinoin and tazarotene have demonstrated efficacy in reducing acne and acne sequelae in several studies. Trifarotene has been extensively studied in Phase 3 trials, demonstrating notable success in treating mild-to-moderate acne. Recently, two large-scale, randomized, blinded, Phase 4 clinical trials investigated trifarotene cream 0.005% in patients with atrophic acne scarring and acne-induced hyperpigmentation across all Fitzpatrick phototypes. The START study found that there was a greater reduction in total atrophic acne scar count in the trifarotene group compared with the vehicle group at Week 24 (55.2% vs 29.9%) with statistical significance established as early as Week 2 (P = 0.001). Based on this evidence, we recommend that topical retinoids should be introduced as first-line therapy for the treatment of acne and acne sequelae. Retinoids should be implemented into a treatment routine as early as possible, especially for patients with darker Fitzpatrick phototypes or patients at risk of atrophic acne scarring. Furthermore, retinoids should be incorporated within a comprehensive skincare regimen that includes adequate photoprotection when treating patients with darker Fitzpatrick phototypes. Finally, management of acne and acne sequelae should include maintenance therapy with topical retinoids. This article supports the American Academy of Dermatology's call for acne sequelae treatment guidance and emphasizes the need for continued research to optimize patient care.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"563-577"},"PeriodicalIF":3.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909303/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143472298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alopecia Areata Incognita: Current Evidence.","authors":"Giselle Rodríguez-Tamez, Narges Maskan-Bermudez, Antonella Tosti","doi":"10.1007/s13555-025-01359-5","DOIUrl":"10.1007/s13555-025-01359-5","url":null,"abstract":"<p><strong>Introduction: </strong>Alopecia areata incognita (AAI) represents a distinct subtype of alopecia areata (AA), characterized by profound hair shedding and diffuse thinning. Despite being initially described in 1987, AAI remains underdiagnosed, with limited published reports. This comprehensive review aims to consolidate the current evidence concerning AAI pathogenesis, clinical presentation, trichoscopic and histopathologic attributes, differential diagnoses, and available treatment modalities.</p><p><strong>Methods: </strong>PubMed searches were performed to identify all articles discussing AAI published up to September 2024.</p><p><strong>Results: </strong>We identified 28 articles encompassing AAI epidemiology, pathogenesis, clinical presentation, trichoscopic findings, histopathologic characteristics, diagnosis, and treatment options.</p><p><strong>Limitations: </strong>The data primarily stem from observational studies, case reports, case series, and a pilot study. The establishment of diagnostic criteria and treatment protocols necessitates more extensive and well-controlled studies.</p><p><strong>Conclusion: </strong>Alopecia areata incognita is a distinctive form of AA, sharing similarities with telogen effluvium (TE) and showing potential associations with androgenetic alopecia (AGA). It has an acute onset and results in sudden diffuse hair loss. While diagnostic challenges persist, combining clinical, trichoscopic, and histopathologic evaluations aids in accurate identification. AAI typically responds favorably to topical steroids and has a better prognosis than other subtypes of AA.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"635-645"},"PeriodicalIF":3.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11908991/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Importance of Surgical Margins in Patients with Early-Stage Merkel Cell Carcinoma.","authors":"Arthur W Cowman, Kristel Lourdault, Douglas Hanes, Sean Nassoiy, Paul Shin, Tyler Aguilar, Melanie Goldfarb, Richard Essner","doi":"10.1007/s13555-025-01345-x","DOIUrl":"10.1007/s13555-025-01345-x","url":null,"abstract":"<p><strong>Introduction: </strong>The National Comprehensive Cancer Network (NCCN) recommends excision of the primary tumor using 1-2-cm surgical margins and sentinel lymph node biopsy (SLNB) as the initial management of early-stage Merkel cell carcinoma (MCC). However, there is no clear consensus on the appropriate size of the surgical margins and/or the use of Mohs micrographic surgery (MMS). Our aim was to demonstrate that, independent of the type of surgery, obtaining negative surgical margins is associated with enhanced overall survival (OS).</p><p><strong>Methods: </strong>A retrospective study was performed using early-stage MCC patients from the National Cancer Database (NCDB) who were diagnosed between 2004 and 2020 and underwent surgical excision (SE) of their primary tumor. Patients were stratified into three groups based on the surgical treatment they received: < 1 cm excision margin, ≥ 1 cm excision margin, or MMS. OS was assessed with Kaplan-Meier curves, log-rank tests, and multivariable risk-adjusted Cox proportional-hazards regression.</p><p><strong>Results: </strong>Of the 4,607 patients included in this study; 53% underwent SE of ≥ 1 cm (n = 2,474), 41% had SE < 1 cm (n = 1,905), and the remainder had MMS (n = 228). 75% of patients had an SLNB, and 56% received adjuvant radiation to the primary site and/or nodal basin. While no difference in OS was observed between the three surgical treatments, negative surgical margins (hazard ratio (HR) 0.78; 95% confidence interval (CI) 0.65-0.94) and receipt of radiation to the primary site (HR 0.82; 95% CI 0.73-0.92) were both independently associated with improved OS.</p><p><strong>Conclusion: </strong>Achieving negative surgical margins is associated with improved OS in MCC, suggesting that MMS and conventional excision are both suitable approaches for the treatment of primary MCC.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"733-746"},"PeriodicalIF":3.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Indirect Comparison Between Bimekizumab and Brodalumab for the Management of Moderate to Severe Psoriasis: A 36-Week Real-Life Study.","authors":"Luca Potestio, Fabrizio Martora, Flavia Raia, Gioacchino Lucagnano, Claudio Brescia, Ginevra Torta, Matteo Megna","doi":"10.1007/s13555-025-01361-x","DOIUrl":"10.1007/s13555-025-01361-x","url":null,"abstract":"<p><strong>Introduction: </strong>Bimekizumab and brodalumab are characterized by a different mechanism of action if compared to the other anti-interleukin (IL)-17s which target IL-17A. Indeed, brodalumab acts on IL-17RA whereas bimekizumab acts on IL-17A, IL-17F, and IL-17AF cytokines. Currently, despite real-life data on the efficacy and safety of bimekizumab and brodalumab have been reported, data comparing these two drugs are absent. However, these data are mandatory to evaluate whether a different target of the same IL can be correlated with a different profile in terms of effectiveness and safety. Moreover, it should be underlined that bimekizumab and brodalumab stood out as the psoriasis treatments with the fastest onset of action, delivering quicker therapeutic responses compared to other drugs acting on IL-17.</p><p><strong>Methods: </strong>A monocentric retrospective study was carried out enrolling patients affected by moderate to severe psoriasis undergoing treatment with brodalumab or bimekizumab. At baseline, clinical demographic details were collected. Clinical improvement [Psoriasis Area Severity Index (PASI), body surface area (BSA)] was collected at weeks 4, 16, and 36. Safety data were analyzed at the same timepoints.</p><p><strong>Results: </strong>A total of 125 patients were enrolled in the study [bimekizumab: 53 (42.40%); brodalumab: 72 (57.6%)]. Psoriasis severity at baseline was similar between the two cohorts. Both PASI and BSA significantly reduced at each follow-up for both treatment cohorts. The bimekizumab group reached a higher percentage of PASI90/PASI100 response at each timepoint as compared to the brodalumab cohort. In particular, the percentage of PASI100 response was significantly higher in the bimekizumab group as compared to the brodalumab cohort at week 4 (41.5% vs 23.6%, p < 0.05) and at week 16 (67.9% vs 48.6%). Discontinuation for ineffectiveness was higher in the brodalumab cohort (8.3%) as compared to the bimekizumab group (3.8%), without statistical significance. As regards safety, two cases of eczematous reactions (bimekizumab: 2, brodalumab: 0), and five cases of candidiasis (bimekizumab: 4, brodalumab: 1) were collected. Overall, 3 (5.7%) and 1 (1.4%) patients discontinued bimekizumab and brodalumab because of adverse events, respectively.</p><p><strong>Conclusion: </strong>Our study confirmed the efficacy and safety of both bimekizumab and brodalumab, up to 36 weeks of treatment. Although both drugs showed a significant improvement of the investigated scores from week 4, some differences in terms of PASI90 and PASI100 responses (higher for bimekizumab at each follow-up, with only PASI100 response significantly higher at week 4 and 16) were registered. No statistical significance was found for safety data and treatment failure.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"721-731"},"PeriodicalIF":3.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909295/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The APOLO Study: A Cross-Sectional Analysis of Disease Characteristics and Patient Burden in Moderate-to-Severe Atopic Dermatitis in Portugal.","authors":"Bruno Duarte, Pedro Mendes-Bastos, Joana Antunes, Filomena Azevedo, Margarida Gonçalo, Martinha Henrique, Vanda Marques, Isabel Freitas, Tiago Torres","doi":"10.1007/s13555-025-01347-9","DOIUrl":"10.1007/s13555-025-01347-9","url":null,"abstract":"<p><strong>Introduction: </strong>Atopic dermatitis (AD) is a chronic inflammatory skin disease with a substantial impact on patients' quality of life (QoL). This study aimed to characterize the burden of moderate-to-severe AD in the Portuguese population, focusing on patients' QoL and socioeconomic activities while describing their treatment patterns and healthcare resource use.</p><p><strong>Methods: </strong>This multicenter, cross-sectional, and non-interventional study in eight Portuguese referral AD centers recruited patients over 12 years old, seeking first-time AD care. Patients over 16 years old were analyzed, and data on demographics, clinical characteristics, treatment patterns, healthcare resource utilization, and burden of disease via patient-reported outcomes (PROs) were collected.</p><p><strong>Results: </strong>With a predominantly White cohort, a mean age of 30.0 years, and balanced gender distribution, the study highlighted the significant impact of moderate-to-severe AD on patients' QoL, with a mean Dermatology Life Quality Index score of 15.19. High levels of itch, lesional skin severity, sleep disturbance, and pain contributed to the substantial burden of disease. Productivity was impaired in 40.0% of patients and daily activities were disrupted in 50.0%. Average body surface area involvement was 45.82%, with a mean of 6.49 AD flares in the previous year. Dermatologists played a pivotal role in the patient journey, contributing significantly to the diagnosis (55.9%) and referral process (70.9%). Treatment patterns highlighted a historical reliance on topical therapies and an evolving landscape with post-visit inclusion of advanced therapies such as dupilumab (38.5%), conventional immunosuppressants like cyclosporine (31.2%), and baricitinib (6.8%).</p><p><strong>Conclusion: </strong>This study unveils the intricate landscape of moderate-to-severe AD in Portugal, highlighting a substantial unmet need for optimal disease management. The role of dermatologists is crucial, yet limited adoption of advanced therapies in the face of significant disease burden prompts critical reflection.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"647-662"},"PeriodicalIF":3.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909302/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Benefits and Satisfaction with Apremilast Treatment in Patients with Psoriasis Affecting the Genital Area: Secondary Analysis of the APPRECIATE Study.","authors":"Neuza da Silva Burger, Kathy V Tran, Methodios Typou, Rachel Sommer, David Neasham, Myriam Cordey, Matthias Augustin","doi":"10.1007/s13555-025-01360-y","DOIUrl":"10.1007/s13555-025-01360-y","url":null,"abstract":"<p><strong>Introduction: </strong>Plaque-type psoriasis affects the genital area in 7-42% of patients, and can impose significant quality of life (QoL) impairments. In this case, systemic treatment is recommended regardless of the affected body surface area. This real-world study compared treatment effects and patient-reported outcomes (PROs) between patients with and without genital lesions, undergoing apremilast treatment for 6 ± 1 months.</p><p><strong>Methods: </strong>Secondary analyses were conducted using data from the observational, retrospective, cross-sectional APPRECIATE study. Adult patients with plaque-type psoriasis who initiated apremilast during the previous 6 ± 1 months were consecutively recruited in seven European countries between May 2016 and November 2019. At the time of study inclusion (T1), clinical and PROs were assessed by physician/patient questionnaires. Baseline data were collected retrospectively from medical records.</p><p><strong>Results: </strong>This study included 482 patients: 108 with genital psoriasis (GenPso+) and 374 without genital lesions (GenPso-). The GenPso+ group had higher disease burden at baseline. For patients receiving ongoing treatment at T1, there was significant improvement in disease severity and marginally significant improvement in QoL impairments, independent of genital involvement. Satisfaction with medication and patient benefits also did not differ between groups.</p><p><strong>Conclusion: </strong>This study further established the value of apremilast as a systemic treatment for patients with psoriasis, including those with genital involvement.</p><p><strong>Trial registration: </strong>The APPRECIATE study was registered at  https://clinicaltrials.gov/  with the number NCT02740218.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"681-695"},"PeriodicalIF":3.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe Paradoxical Scalp Psoriasis Induced by Bimekizumab in a Young Multifailure Hidradenitis Suppurativa Patient.","authors":"Fabrizio Martora, Teresa Battista, Luca Potestio, Matteo Megna","doi":"10.1007/s13555-025-01364-8","DOIUrl":"10.1007/s13555-025-01364-8","url":null,"abstract":"<p><p>This article explores the ongoing research into the complex pathogenesis of hidradenitis suppurativa (HS) and the persistent challenges in finding effective treatments. With 113 clinical studies currently listed on ClinicalTrials.gov, the quest for novel therapeutic approaches for HS remains vigorous. In this context, bimekizumab stands out as a promising option-a fully humanized IgG monoclonal antibody that selectively targets both interleukin (IL)-17A and IL-17F, showing rapid and significant improvements in HS disease activity. The case study presented in this article features a 24-year-old woman with HS, whose previous treatments had been unsuccessful until she began therapy with bimekizumab. While the patient experienced marked improvement in her HS symptoms, she developed paradoxical scalp psoriasis, complicating her treatment plan. This case highlights not only the therapeutic potential of bimekizumab but also the need for careful monitoring and management of possible adverse effects. Furthermore, the article emphasizes the need for additional research to confirm the efficacy of bimekizumab in larger patient groups, possibly through phase 3 clinical trials and real-world studies. It also underscores the importance of developing comprehensive management strategies for paradoxical reactions, which may become more common as new treatment options for HS are introduced. In summary, the article reflects the evolving landscape of HS treatment, with bimekizumab representing a promising advancement. However, it calls for careful consideration of potential adverse events and the need for further research to solidify its role in HS management.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"763-769"},"PeriodicalIF":3.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909332/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143522850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}